Research location
Ottignies
Belgium
Advertisement
Research activity in Ottignies
BelgiumCureCurrent currently publishes aggregate city-level research activity for this location: 83 trials and 84 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ottignies
83 linked trials · page 1 of 2Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsNCT07106632 · 2026-06-26 · 1 site observation
RECRUITING
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation
RECRUITING
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT07164443 · 2025-09-02 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18 · 1 site observation
RECRUITING
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21 · 1 site observation
RECRUITING
DESTINY Breast Respond HER2-(Ultra)Low EuropeNCT05945732 · 2023-10-24 · 1 site observation
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)NCT04916613 · 2022-04-19 · 1 site observation
RECRUITING
BIO|MASTER.CSP StudyNCT06620237 · 2024-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.NCT05962606 · 2024-02-02 · 1 site observation
COMPLETED
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)NCT05555732 · 2023-01-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · 2022-03-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Lerociclib in Participants With Advanced Breast CancerNCT05085002 · 2021-12-21 · 1 site observation
TERMINATED
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureNCT04988295 · 2021-11-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerNCT04556773 · 2020-12-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT04487080 · 2020-09-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)NCT04497844 · 2020-09-23 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerNCT03988114 · 2019-09-16 · 1 site observation
WITHDRAWN
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBCNCT03905343 · 2019-06-25 · 1 site observation
TERMINATED
BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in BelgiumNCT03959137 · 2019-06-03 · 1 site observation
COMPLETED
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT03778931 · 2019-05-10 · 1 site observation
COMPLETED
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate CancerNCT03871816 · 2019-04-22 · 1 site observation
COMPLETED
Treatment Resistance Following Anti-cancer TherapiesNCT04436120 · 2019-02-13 · 1 site observation
TERMINATED
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCNCT03616886 · 2018-12-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)NCT03369665 · 2018-06-20 · 1 site observation
COMPLETED
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.NCT03330847 · 2018-03-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCNCT03395197 · 2017-12-18 · 1 site observation
ACTIVE_NOT_RECRUITING
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesNCT02854436 · 2016-08-31 · 1 site observation
COMPLETED
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.NCT02555683 · 2015-12-11 · 1 site observation
COMPLETED
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.NCT02437318 · 2015-07-23 · 1 site observation
COMPLETED
Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast CancerNCT04224922 · 2015-05-01 · 1 site observation
COMPLETED
A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide AloneNCT02288247 · 2014-12-01 · 1 site observation
COMPLETED
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT02257736 · 2014-11-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection FractionNCT01920711 · 2014-07-18 · 1 site observation
COMPLETED
Efficacy and Safety Study of Ozanimod in Relapsing Multiple SclerosisNCT02047734 · 2013-12-03 · 2 site observations
COMPLETED
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate CancerNCT01946204 · 2013-10-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical CareNCT02236637 · 2013-06-14 · 1 site observation
COMPLETED
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)NCT01715285 · 2013-02-12 · 1 site observation
COMPLETED
BIOFLOW-III Belgium Satellite RegistryNCT01831336 · 2013-02-01 · 1 site observation
COMPLETED
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis PatientsNCT01628393 · 2012-09-18 · 1 site observation
COMPLETED
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K ActivationNCT01572727 · 2012-08-01 · 1 site observation
COMPLETED
A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in MonotherapyNCT01705730 · 2012-07-31 · 1 site observation
COMPLETED
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone MetastasesNCT01618370 · 2012-07-22 · 1 site observation
COMPLETED
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine TreatmentNCT01564056 · 2012-04-12 · 1 site observation
COMPLETED
Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With AnthracyclinesNCT01555944 · 2012-02-01 · 1 site observation
COMPLETED
An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line TherapyNCT01664533 · 2011-09-01 · 1 site observation
COMPLETED
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate CancerNCT01308580 · 2011-04-01 · 1 site observation
COMPLETED
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia PatientsNCT01328093 · 2011-04-01 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.